Skip to content
10-Q

Quarterly Report

Anika Therapeutics, Inc. ANIK

0001171843-25-004826

← back to feed
Filed
Jul 30, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 23, 2025 14.42M sh
Shares Diluted Q2 2025 · Jun 30, 2025 14.52M sh
Shares Diluted Q2 2025 · Jun 30, 2025 14.33M sh
Shares Diluted restated Q2 2025 · Jun 30, 2024 14.86M sh
Shares Diluted Q2 2025 · Jun 30, 2024 14.77M sh
Stock Repurchased Q2 2025 · Jun 30, 2025 $3.97M
Stock Repurchased Q2 2025 · Jun 30, 2024 $1.37M
Capex Q2 2025 · Jun 30, 2025 $4.29M
Capex Q2 2025 · Jun 30, 2024 $5.21M
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$319K
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$1.2M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $53.17M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $55.63M
Stockholders Equity Q2 2025 · Jun 30, 2025 $147.67M
Stockholders Equity Q2 2025 · Mar 31, 2025 $148.4M
Stockholders Equity Q2 2025 · Dec 31, 2024 $153.99M
Stockholders Equity Q2 2025 · Jun 30, 2024 $210.34M
Stockholders Equity Q2 2025 · Mar 31, 2024 $208.54M
Stockholders Equity Q2 2025 · Dec 31, 2023 $212.27M
Current Liabilities Q2 2025 · Jun 30, 2025 $16.08M
Current Liabilities Q2 2025 · Dec 31, 2024 $23.31M
Current Assets Q2 2025 · Jun 30, 2025 $99.32M
Current Assets Q2 2025 · Dec 31, 2024 $113.65M
Total Assets Q2 2025 · Jun 30, 2025 $187.68M
Total Assets Q2 2025 · Dec 31, 2024 $202.74M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.28
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.62
Eps Diluted restated Q2 2025 · Jun 30, 2024 $0.00
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.31
Eps Basic Q2 2025 · Jun 30, 2025 −$0.28
Eps Basic Q2 2025 · Jun 30, 2025 −$0.62
Eps Basic Q2 2025 · Jun 30, 2024 −$0.01
Eps Basic Q2 2025 · Jun 30, 2024 −$0.31
Sga Expense Q2 2025 · Jun 30, 2025 $12.23M
Sga Expense Q2 2025 · Jun 30, 2025 $25.14M
Sga Expense restated Q2 2025 · Jun 30, 2024 $15.62M
Sga Expense restated Q2 2025 · Jun 30, 2024 $30.69M
Rd Expense Q2 2025 · Jun 30, 2025 $6.31M
Rd Expense Q2 2025 · Jun 30, 2025 $12.37M
Rd Expense restated Q2 2025 · Jun 30, 2024 $6.68M
Rd Expense restated Q2 2025 · Jun 30, 2024 $13.09M
Net Income Q2 2025 · Jun 30, 2025 −$3.97M
Net Income Q2 2025 · Jun 30, 2025 −$8.84M
Net Income Q2 2025 · Mar 31, 2025 −$4.87M
Net Income Q2 2025 · Jun 30, 2024 −$88K
Net Income Q2 2025 · Jun 30, 2024 −$4.6M
Net Income Q2 2025 · Mar 31, 2024 −$4.51M
Operating Income Q2 2025 · Jun 30, 2025 −$4.18M
Operating Income Q2 2025 · Jun 30, 2025 −$8.46M
Operating Income restated Q2 2025 · Jun 30, 2024 −$1.81M
Operating Income restated Q2 2025 · Jun 30, 2024 −$4.32M
Gross Profit Q2 2025 · Jun 30, 2025 $14.36M
Gross Profit Q2 2025 · Jun 30, 2025 $29.04M
Gross Profit restated Q2 2025 · Jun 30, 2024 $20.49M
Gross Profit restated Q2 2025 · Jun 30, 2024 $39.46M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $13.86M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $25.34M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $10.24M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $20.28M
Revenue Q2 2025 · Jun 30, 2025 $28.22M
Revenue Q2 2025 · Jun 30, 2025 $54.39M
Revenue restated Q2 2025 · Jun 30, 2024 $30.72M
Revenue restated Q2 2025 · Jun 30, 2024 $59.75M